Navigation Links
Melanoma Drug Boosts Recurrence-Free Survival
Date:7/11/2008

Pegylated inteferon cut risk 15% but did not reduce overall mortality rates

FRIDAY, July 11 (HealthDay News) -- A chemically modified form of interferon improves the chances that melanoma patients will survive and have no recurrence of the skin cancer, according to a new report.

Dutch researchers, who published their findings in this week's edition of The Lancet, said their study found long-term treatment with pegylated IFNa2b cut the risk of a recurrence by 15 percent over a four-year period.

However, the patients' overall survival rates did not improve, and the treatment was discontinued in 30 percent of the 627 patients because of toxicity. The most common side effects in all patients were liver toxicity, fatigue and depression.

In an accompanying comment in The Lancet, two American doctors concluded that the treatment is still worthwhile, however.

"For the large group of patients with melanoma found in their sentinel node, we believe this regimen will be an attractive alternative to high-dose interferon. Some patients with macroscopic nodal disease who would not tolerate or accept high-dose interferon will also want to consider this approach," wrote Vernon Sondak, of the University of South Florida College of Medicine in Tampa, and Lawrence Flaherty, of the Wayne State University School of Medicine in Michigan.

More information

The National Cancer Institute has more about melanoma.



-- Kevin McKeever



SOURCE: The Lancet, news release, July 10, 2008


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved

Page: 1

Related medicine news :

1. Melanoma Diagnosis Often Delayed for Rural Poor
2. Melanoma drug revs immune cells but cancer cells ignore it
3. Promising drug combination may help those with ocular melanoma that has spread
4. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
5. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
6. New type of drug shows promise in attacking melanoma in an innovative way
7. Genes Unlock New Treatments for Deadly Melanoma
8. Top-Line Data Available from Three Ipilimumab Pivotal Trials in Patients with Advanced Metastatic Melanoma
9. Researchers Hone in on Cancer Stem Cells for Melanoma
10. Melanomas may appear noticeably different than other moles
11. Melanomas Present Unique Appearance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/25/2017)... , ... April 25, 2017 , ... A stressful work ... work can also decrease overall productivity and performance in the workplace. The goal of ... During the last few weeks of April, Clearview Resolution Services will be shutting down ...
(Date:4/25/2017)... ... April 25, 2017 , ... Patients who would like to ... a fraction of the time as traditional braces – Wilckodontics®. Dr. Victoria Chen, ... offers this revolutionary treatment with or without a referral. , Wilckodontics is ...
(Date:4/25/2017)... ... 25, 2017 , ... Saad B. Chaudhary, MD is committed to providing the highest quality of ... I focus on preventative care with all my patients to alleviate possible future issues. I ... free to contact my office and my trained staff will assist you in any way ...
(Date:4/25/2017)... ... April 25, 2017 , ... Amendia, ... continuation of its strategic partnership with and platinum sponsorship of Global Spine Outreach ... safe and effective management of complex spine deformity cases, particularly in children. , ...
(Date:4/24/2017)... ... April 24, 2017 , ... Ridgecrest Herbals makes it a point ... strategies to reduce waste, and support renewable energy. They believe this is a crucial ... to find solutions for health issues, and maintain that destroying the environment in the ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... , April 20, 2017  CVS Pharmacy, the ... unveiled a new store design to enhance the ... healthier food, health-focused products and expanded beauty selections ... help customers discover new offerings. Together with its ... evolution of the customer experience at CVS Pharmacy.  ...
(Date:4/20/2017)... 2017  AbbVie (NYSE: ABBV), a global biopharmaceutical ... chronic hepatitis C virus (HCV) infected patients with ... compensated cirrhosis (Child-Pugh A) achieved sustained virologic response ... its investigational, pan-genotypic regimen of glecaprevir/pibrentasvir (G/P). These ... 12 weeks of G/P treatment without ribavirin. Patients ...
(Date:4/20/2017)... PARIS , April 20, 2017 ... EyeCET platform, the first non-viral gene expression technology that ... in the eye to address a wide range of ... UK Medicines and Healthcare products Regulatory Agency (MHRA) to ... ...
Breaking Medicine Technology: